Stock Movers
Stock Movers

Aug 26, 2026 · 7 min

Markets weigh Meta safeguards, Nvidia expectations and cancer-drug promise

Meta Gains on Settlement, Nvidia Dips Ahead of Earnings, RevMed Rallies

The episode connects immediate market reactions to deeper questions about platform accountability, AI-driven growth, drug access and urban planning.

3 key takeaways
  1. 1Meta gains as proposed settlements would require stronger safeguards for young users across its platforms.
  2. 2Nvidia faces investor scrutiny ahead of earnings, with continued AI growth priced against the risk of disappointment.
  3. 3Revolution Medicines rallies after approval of a pancreatic cancer treatment balancing survival gains, quality of life and high cost.

Don't miss

The Revolution Medicines segment weighs the promise of improved survival and quality of life against the treatment’s high annual list price.

The brief

Meta gains after proposed multistate settlements over alleged platform harms would require stronger protections for young users, putting accountability directly into the market story.

Nvidia heads into closely watched earnings with expectations for continued AI-driven growth—and a clear risk that even strong results could disappoint investors.

Revolution Medicines rallies after U.S. approval of a treatment for advanced pancreatic cancer, as the discussion weighs improved survival against its high annual list price.

The episode closes by previewing a broader smart-cities discussion: Dubai is using AI, innovation and long-term planning to manage rapid population growth.

What was said on this episode

8 statements · 6 positive · 2 negative

  1. Lisa Matteoon Meta stock reactionPositive1:55

    Meta’s initial stock selloff quickly faded after the settlement news.

    “the initial reaction faded so fast”

    Listen at 1:55

  2. Lisa Matteoon NVIDIA earningsNegative2:41

    NVIDIA could disappoint investors even if it meets projected earnings numbers.

    “This can still be a big disappointment for investors, even if they reach those numbers.”

    Listen at 2:41

  3. Lisa Matteoon AI chip pricesNegative2:54

    AI chip prices may rise more than 15% as memory costs surge.

    “People say that AI chips will rise more than 15% in some cases, surging memory costs.”

    Listen at 2:54

  4. Tim Stenebeckon Revolution Medicines pancreatic cancer drugPositive4:22

    Patients receiving Revolution Medicines’ drug survived more than 13 months in the trial.

    “those who received this drug survived for more than 13 months.”

    Listen at 4:22

  5. Lisa Matteoon Pancreatic cancer treatmentsPositive4:38

    These treatments allow patients to remain home with their families more than alternatives.

    “these treatments allow people to stay at home and be with their families compared to other treatments.”

    Listen at 4:38

  6. Rohit Krishnanon AI in smart citiesPositive5:34

    AI will compress processes in smart-city development.

    “AI will allow in the smart city space to compress a lot of things.”

    Listen at 5:34

  7. Estefanía Tapiason Dubai urban planning responsePositive6:00

    Dubai responded effectively to its sudden population increase.

    “they reacted very well to it.”

    Listen at 6:00

  8. Estefanía Tapiason Dubai urban planningPositive6:02

    Dubai has a long-term urban planning vision.

    “They have a long-term urban planning vision”

    Listen at 6:02

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Books & mentions

Listen to the full episode and explore every guest, topic, and moment on PodLume.

What is PodLume?

PodLume turns podcasts into searchable knowledge. AI-decoded transcripts, identified guests and topics, smart highlights, and cross-show search across the world’s best conversations — all in your pocket.

Markets weigh Meta safeguards, Nvidia expectations and cancer-drug promise | PodLume